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Evidence suggests that disturbances in neurobiological mechanisms of reward and inhibitory control maintain addiction and provoke
relapse during abstinence. Abnormalities within the dopamine system may contribute to these disturbances and pharmacologically
targeting the D3 dopamine receptor (DRD3) is therefore of significant clinical interest. We used functional magnetic resonance imaging to
investigate the acute effects of the DRD3 antagonist GSK598809 on anticipatory reward processing, using the monetary incentive delay
task (MIDT), and response inhibition using the Go/No-Go task (GNGT). A double-blind, placebo-controlled, crossover design approach
was used in abstinent alcohol dependent, abstinent poly-drug dependent and healthy control volunteers. For the MIDT, there was
evidence of blunted ventral striatal response to reward in the poly-drug-dependent group under placebo. GSK598809 normalized ventral
striatal reward response and enhanced response in the DRD3-rich regions of the ventral pallidum and substantia nigra. Exploratory
investigations suggested that the effects of GSK598809 were mainly driven by those with primary dependence on alcohol but not on
opiates. Taken together, these findings suggest that GSK598809 may remediate reward deficits in substance dependence. For the GNGT,
enhanced response in the inferior frontal cortex of the poly-drug group was found. However, there were no effects of GSK598809 on the
neural network underlying response inhibition nor were there any behavioral drug effects on response inhibition. GSK598809 modulated
the neural network underlying reward anticipation but not response inhibition, suggesting that DRD3 antagonists may restore reward
deficits in addiction.
Neuropsychopharmacology (2017) 42, 1049–1057; doi:10.1038/npp.2016.289; published online 25 January 2017
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INTRODUCTION
Evidence suggests dysregulation of neurobiological networks
involved in reward processing and inhibitory control
contributes to the risk and maintenance of addiction and
relapse during abstinence. Disturbances in reward function-
ing involve hyporesponsivity to non-drug reward, which is
associated with increased craving, drug use, and brain
response to drug-related stimuli (Blum et al, 2000; Lubman
et al, 2009; Wrase et al, 2007). Failures of impulse control
across a range of domains have been a consistent finding in
addiction and are associated with relapse (Taylor et al, 2016).
fMRI studies implicate reduced recruitment of lateral and
medial prefrontal regions in impaired impulse control
(Forman et al, 2004; Kaufman et al, 2003), although
enhanced recruitment has been found in those who have
successfully achieved abstinence from cocaine (Connolly
et al, 2012).
Abnormalities in reward and impulse control may be
effects of blunted dopamine signaling in addiction (Trifilieff
and Martinez, 2014). Reductions in dopamine release and
receptor density are associated with increased drug use and
craving and may precede the development of addiction
(Casey et al, 2014; Heinz et al, 2004). Dopamine has a pivotal
role in reward-related behaviors, mediating reward learning
(Schultz, 1998) and ‘incentive salience’ of reward stimuli
(Robinson and Berridge, 1993). Deficits in dopamine
neurotransmission may impair impulse control, as low
striatal D2/D3 binding is associated with increased impul-
sivity in rodents and humans (Clark et al, 2012; Ghahremani
et al, 2012). Drugs increasing extracellular dopamine
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improve response inhibition in cocaine and alcohol depen-
dence (Garrison and Potenza, 2014). These lines of evidence
suggest that increasing brain dopamine may be a useful
therapeutic strategy for addiction (Nutt et al, 2015).
The D3 receptor (DRD3) is preferentially expressed within
ventral striatal and limbic brain regions involved in reward
processing. In vitro studies demonstrate the highest density
of DRD3s within the ventral striatum of the human brain
(Gurevich and Joyce, 1999), whereas in vivo human positron
emission tomography (PET) studies demonstrated maximal
DRD3 density within the ventral pallidum (VP), followed by
the substantia nigra (SN) and ventral striatum (VS), with
lower levels in thalamus and dorsal striatum (Tziortzi et al,
2011). Exposure to drugs of abuse results in upregulation of
DRD3 in rodent models of addiction (Le Foll and Di Ciano,
2015). Upregulated DRD3 density has been found within the
VS and SN in a postmortem study of cocaine dependence
(Staley and Mash, 1996) while upregulated nigral DRD3s
correlated positively with impulsivity and risky decision
making in stimulant dependence (Boileau et al, 2012; Payer
et al, 2014). Trends for upregulated ventral pallidal DRD3
have been found in both alcohol dependence and heavy
stimulant use (Boileau et al, 2012; Erritzoe et al, 2014).
Consequently, there is much interest in this receptor as a
target for drug therapy.
DRD3 antagonists have shown promise in preclinical
studies, reducing self-administration, cue-induced drug-
seeking, and conditioned place preference (Heidbreder and
Newman, 2010). In clinical populations, the novel DRD3
antagonist GSK598809 transiently reduced craving in
nicotine dependence (Mugnaini et al, 2013) and attentional
bias for food cues in low restrained eaters (Nathan et al,
2012). The exact mechanism by which DRD3 antagonists
achieve these effects is currently unknown, although there is
evidence that the DRD3 is an autoreceptor controlling the
synthesis and release of dopamine (Diaz et al, 2000; Zapata
and Shippenberg, 2002). Blockade of DRD3 with GSK598809
may therefore increase extra-synaptic dopamine.
The ICCAM Platform study is a multicenter research study
that aimed to (1) identify brain networks underlying
addiction to alcohol, cocaine, and opiates and relapse
vulnerability and (2) identify potential new treatments for
addiction based on their ability to modulate these networks.
Here we present the effects of GSK598809 on networks
underlying the anticipation of reward, using the monetary
incentive delay task (MIDT; Knutson et al, 2000) and
response inhibition using the Go/No-Go task (GNGT;
Garavan et al, 2002). We hypothesized that reward and
inhibitory control disturbances would be found in abstinent
drug-dependent individuals and that GSK598809 would
mitigate such disturbances.
MATERIALS AND METHODS
Participants
Participants were recruited as part of the ICCAM multi-
center study. Detailed description of recruitment and
participant characteristics are described elsewhere
(Paterson et al, 2015). Briefly, substance-dependent indivi-
duals were recruited according to the following criteria: aged
20–64 years, meeting DSM-IV (American Psychiatric
Association, 2000) criteria for current or prior alcohol,
cocaine or opiate dependence, abstinent for at least 4 weeks,
free from any current primary axis-1 mental health disorder,
no history of severe enduring mental illness, no psychoactive
medications, no serious physical health problems, no
neurological disease, and no contraindications for MRI
scanning. Healthy controls (HC) were recruited according to
the same criteria except that they had no current or history
of dependence to any drug except nicotine.
Eighty-eight participants completed both placebo and
GSK598809 sessions: a HC group (n= 35), an abstinent
alcohol-dependent (AD) (n= 20) and an abstinent poly-
drug-dependent (PD) group (n= 33). Five people were
excluded from the MID analysis, and 14 from the GNG
analysis leaving final Ns of 83 and 74, respectively (see
Supplementary Materials for details).
The HC group was matched with the AD and PD groups
for age, sex, smoking status, and handedness and additionally
with the AD group, but not the PD group, for IQ and years of
education (see Supplementary Tables S1 and S2). AD and PD
groups differed significantly for age for the MID analysis,
with a trend for a difference for the GNG analysis (p= 0.06).
Procedures and Tasks
Procedures are described in detail elsewhere (Paterson et al,
2015). Briefly, the ICCAM study involved five separate
scanning sessions (one screening, including fMRI scanning
to familiarize participants with the scanner environment and
tasks, and four drug testing sessions). Placebo and
GSK598809 (60 mg) were administered in a double-blind
manner with a crossover design. Owing to concerns over
study dropout and loss of placebo data, a weighted
randomization was used with the placebo session adminis-
tered in study session 2 or 3, whereas GSK598809 was
administered in session 4 or 5 (with the other two sessions
testing other drugs as part of the ICCAM platform; Paterson
et al, 2015). The mean (SD) inter-session interval between
placebo and GSK598809 sessions was 34.39 days (40.91)
(MIDT) and 36.15 days (42.72) (GNGT), with no difference
between groups; MID (F(2.80)= 0.25, p= 0.78), GNG
(F(2,71)= 0.03, p= 0.98).
Scans occurred 2 h after administration of drug or placebo
and tasks were practiced before scanning. All participants
had an alcohol breathalyzer reading of 0.0%. Participants
were urine screened. A positive test for cannabis was allowed
owing to its long half-life provided there was no use in the
previous week. Participants tested negative for all other
drugs, with two allowed exceptions (see Supplementary
Materials).
Tasks
Both the MIDT and GNGT are described in detail within
Supplementary Materials.
The MIDT was modified from Knutson et al (2000) and
was designed to probe reward sensitivity. Participants could
win or lose money (or neither win nor lose) depending upon
how quickly they reacted to a target stimulus that was
predicted by a win, loss, or neutral cue. The task was
designed such that win accuracy would be 66% and £10
would be won at each session.
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The GNGT was an event-related task adapted from
Garavan et al (2002), consisting of a series of letter Xs and
letter Ys. Participants were instructed to respond as fast as
they could to each letter (Go trial) except when the letter was
the same as the previous letter (No-Go trial).
Analysis of Behavioral Data
For the MIDT, reward-neutral reaction time (RT) was
analyzed. For the GNGT, percentage accuracy for Go trials
and No-Go trials and RT for Go trials were analyzed. All
analyses used mixed ANOVAs with drug session as the
within-subject factor and group as the between-subject
factor. Age was included as a mean-adjusted covariate in
all analyses.
Analysis of fMRI Data
Details of data acquisition and preprocessing are in
Supplementary Materials.
For the MIDT, analysis focused on the ‘cue and
anticipation’ phase and was modeled as a mini-block
beginning at the cue onset and ending at the onset of the
target stimulus (see Supplementary Materials for details).
The contrast of interest is the average of the ‘reward cue
anticipation’ compared with ‘neutral cue anticipation’ across
both runs.
For the GNGT, successful inhibitions of No-Go trials
(‘stops’) and unsuccessful No-Gos (‘errors’) were modeled
against an implicit baseline of Go trials. Stops that were
preceded by a Go trial that also did not have a response were
considered ‘fake inhibitions’ and were modeled separately as
conditions of no-interest. The task was powered to look at
‘stops’ rather than ‘errors’, therefore only the ‘stops4go’
contrast is explored further.
Realignment parameters and movement outliers (scan-to-
scan displacement of 43 mm) were added to the models as
nuisance regressors.
A region of interest (ROI) approach was used. ROIs of the
VS, VP, and SN were chosen for the MIDT owing to their key
roles in reward processing (Haber and Knutson, 2010) and
evidence of abnormalities within these regions in addiction.
Additionally, as reviewed above, these regions are particularly
rich in DRD3s and therefore are potential targets for
GSK598809 effects. For the GNGT, bilateral inferior frontal
gyri (IFG) and anterior cingulate cortex were chosen owing to
their key role in motor inhibition (Aron et al, 2003) and
abnormal recruitment in addiction. While not key ROIs for
this task, exploratory investigations were also carried out with
the DRD3-rich regions of VS, VP, and SN.
Mean reward-neutral (MID) and stop-go (GNG) contrast
estimates were extracted from the relevant ROIs for each
participant and entered into mixed ANOVAs (see
Supplementary Materials for details). A Bonferroni’s correc-
tion for the three regions investigated for each task was
applied, with significance set at po0.017. Additional
exploratory whole-brain investigations were carried out
using a voxel-wise threshold of po0.05, Family-Wise Error
Figure 1 Regions of interest: (a) ROIs for the MID task, left/blue (when in color) shows the ventral striatum, middle/red shows the ventral pallidum (both
defined according to the guidelines of Tziortzi et al, 2011), and right/yellow shows the substantia nigra. (b) ROIs for the GNG task, left/cyan shows the right
inferior frontal gyrus, middle/green shows the left inferior frontal gyrus, and right/purple shows the anterior cingulate.
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Corrected (see Figure 1 for ROIs and Supplementary
Materials for further details).
Correlational analyses were additionally carried out to
investigate the relationships between ROI brain response and
performance, reward and impulsivity variables, ROI brain
response and duration of abstinence, and drug effects on ROI
response and performance (see Supplementary Materials for
details). Twenty-nine analyses were carried out and
Bonferroni-corrected significance was set at po0.0017.
RESULTS
MID Behavioral
There were no significant drug or group effects or interac-
tions for MID performance (see Supplementary Figure S1).
MID fMRI
Effect of task. The reward-neutral contrast for each group
for both the placebo and GSK598809 conditions revealed a
highly significant network of activation, including the VP,
VS, and SN, in line with previous studies (Knutson et al,
2000). See Supplementary Figure S3.
Effects of group and drug: whole-brain analysis. Mixed
ANOVAs demonstrated a significant main effect of drug
within the left VP, caudate, and cerebellum (Table 1 and
Supplementary Figure S5). These effects appear to be driven
by increased reward-neutral anticipation response in the
GSK598809 session compared with the placebo session, in
particular for the AD group and to a lesser extent the PD
group. However, these apparent interactions were not
significant.
A significant effect of drug was also observed in the right
middle frontal gyrus (corresponding to the dorsolateral
prefrontal cortex (DLPFC), see Table 1 and Supplementary
Figure S3), which was driven by a significant group-by-drug
session interaction. GSK598809 increases reward-neutral
BOLD response to a greater degree in the AD group
compared with both the HC and PD groups.
ROI analysis. Mixed ANOVAs demonstrated a main effect
of drug within the VS (p= 0.005), VP (po0.001), and SN
(p= 0.009) (Table 1). These effects are due to increased
reward-neutral BOLD response in the GSK598809 session
compared with the placebo session (Figure 2). Although
these effects appear to be mainly driven by the dependent
groups in each ROI, only a trend for a drug-by-group
interaction was found and only in the VP (p= 0.041,
Table 1). Post hoc paired t-tests revealed a significant effect
of GSK598809 on VP reward-neutral BOLD response within
the AD group (po0.001) and PD group (p= 0.003) but not
the HC group (p= 0.145).
No significant main effects of group were found although
trends were found within the VS and SN (p= 0.048 and
0.042, respectively). Figure 2 suggests that these effects were
driven by blunting occurring within the placebo condition of
the PD group. Exploratory post hoc investigations carried out
with the placebo session data only demonstrated a significant
main effect of group in the VS (F(2,79)= 5.03, p= 0.009,
PDoHC) and a trend for a significant blunting in the SN
that just fell short of Bonferroni-corrected significance, (F
(2,79)= 5.03, p= 0.022, PDoHC). Post hoc tests revealed no
difference or trends between AD and HC or AD and PD. No
group effects or trends emerged for corresponding analysis
of the GSK598809 session.
Additional exploratory investigations were carried out
within the ROIs, separating the groups by primary drug of
dependence (see Supplementary Materials). This suggested
that drug effects were driven by participants with a primary
alcohol but not opiate dependence (see Supplementary
Figure S7). Investigations into primary cocaine dependence
were not carried out owing to small numbers.
GNG Behavioral
There were no significant drug or group effects or
interactions for GNG performance (see Supplementary
Figure S1).
GNG fMRI—Effect of Task
The stops4go contrast for each group for both the placebo
and GSK598809 conditions revealed a highly significant
network of activation, in line with previous studies using this
task (Garavan et al, 2002). See Supplementary Figure S4.
Effects of group and drug: whole-brain analysis. Whole-
brain analyses using mixed ANOVAs revealed a significant
group effect within the left cerebral peduncle region of the
midbrain owing to increased activation in the AD group
(Supplementary Figure S6). No drug effects or interactions
were found.
ROI analysis. There was no effect of GSK598809 in any of
the ROIs. A main effect of group was found in the right IFG
(F(2,)= 4.71, p= 0.012), and at trend level in the left IFG
(p= 0.024), driven by hyperactivation in the PD compared
with the HC group (p= 0.016). See Figure 3.
Exploratory analysis revealed no significant effects of
GSK598809 in DRD3-rich regions (VS, VP, SN).
Correlational Analyses
Ventral striatal ROI activation during the placebo condition
for the MIDT, in all participants, correlated with impulsivity
measured by the Barratt Impulsivity Scale (BIS) (Patton et al,
1995) (r=− 0.368, p= 0.001) but not the reward responsivity
subscale of the BISBAS (Carver and White, 1994)
(Supplementary Table S4). To rule out the possibility of this
negative association being primarily driven by group
differences, an additional correlation was carried out within
the healthy control group only, which supported this
negative relationship (r=− 0.372, p= 0.033). No correlations
were found with any of the GNG ROIs (Supplementary
Table S3 and S4). No relationships were found between the
MID and GNGT ROI activation or fMRI and questionnaire
behavioral measures (Supplementary Table S4) or with
duration of abstinence (Supplementary Table S5). No
relationship was found between the effect of GSK598809
on VP activation and MID performance (Supplementary
Table S6).
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DISCUSSION
This study aimed to investigate the effects of the selective
DRD3 antagonist GSK598809 on networks involved in the
anticipation of reward and response inhibition. The main
findings were that GSK598809 significantly increased
reward-neutral reward anticipatory responses for the MIDT
but had no effects on brain response during response
inhibition.
Group effects were found for both tasks, although in
opposite directions. Blunting of the VS in the PD group and
DLPFC response in the AD group was found for the MIDT
under placebo. Enhanced inferior frontal response in the PD
group and enhanced midbrain response in the AD group was
found for the GNGT. There were no effects of either drug or
group on task performance, therefore all reported differences
in BOLD response occur in the context of normal
performance.
MID
Deficits in ventral striatal reward-related signaling are
hypothesized to confer vulnerability to addiction and relapse
(Trifilieff and Martinez, 2014; Blum et al, 2000). We found
blunted ventral striatal response in the PD group, and an
overall negative correlation between VS response and
impulsivity. Reduced MID VS response associated with
increased impulsivity has been previously demonstrated in
alcohol dependence (Beck et al, 2009; Wrase et al, 2007),
therefore our finding adds to a growing literature supporting
the reward deficiency hypothesis of addiction. In contrast to
the studies above, we did not find significant blunting in the
AD group. This could suggest recovery with long-term
abstinence in our cohort; however, we did not find a
significant association between the length of abstinence and
ventral striatal response in the AD group, perhaps owing to
small sample size.
There was a general restorative or enhancing effect of
GSK598809 on reward anticipatory BOLD response. This
finding is in line with evidence suggesting that D3 receptors
may act as autoreceptors, inhibiting dopamine synthesis and
release (Diaz et al, 2000; Zapata and Shippenberg, 2002). It
has been hypothesized that tonic extracellular dopamine may
inhibit phasic dopamine reward signaling via actions on
autoreceptors (Grace, 1991). This may explain the opposing
Table 1 Results from ROIs and Whole-brain Analyses for the MID (Top Two Subtables) and GNG (Bottom Two Subtables) Tasks
MID ROI analysis
Region Effect of drug Group×drug interaction Effect of group
Ventral striatum F(1,79)= 8.35, p= 0.005, GSK4PBO F(2,79)= 1.31, p= 0.28, NS F(2,79)= 3.16, p= 0.048, NS
Ventral pallidum F(1,79)= 30.83, po0.001, GSK4PBO F(2,79)= 3.32, p= 0.041, NS F(2,79)= 2.01, p= 0.141, NS
Substantia nigra F(1,79)= 7.28, p= 0.009, GSK4BPO F(2,79)= 0.86, p= 0.43, NS F(2,79)= 3.29, p= 0.042, NS
MID whole brain
Contrast Region Cluster size MNI coordinates F-value p-Value (FWE corrected) Direction
Main effect of the drug Ventral pallidum 11 − 15,5,− 10 34.77 0.001 GSK4Plac
Middle frontal gyrus 11 30,29,29 29.22 0.003 GSK4Plac
Right cerebellum 9 39,− 49,− 28 27.81 0.007 GSK4Plac
Caudate 19 − 15,− 1,20 26.51 0.01 GSK4Plac
Drug session × group Middle frontal gyrus 6 30,32,32 29.22 0.003 GSK4PBO, AD4HC, PD
Main effect of the group No significant clusters
GNG ROI analysis
Region Effect of drug Group×drug interaction Effect of group
Right inferior frontal gyrus F(1,70)= 1.66, p= 0.20, NS F(2,70)= 0.88, p= 0.42, NS F(2,70)= 4.45,p= 0.015, PD4HC
Left inferior frontal gyrus F(1,70)= 0.35, po0.56, NS F(2,70)= 1.12, p= 0.29, NS F(2,70)= 3.49, p= 0.036, NS
Anterior cingulate cortex F(1,70)= 0.99, p= 0.32, NS F(2,70)= 1.02, p= 0.37, NS F(2,70)= 3.29, p= 0.119, NS
GNG whole brain
Contrast Region Cluster size MNI coordinates F-value p-Value (FWE corrected) Direction
Main effect of the drug No significant clusters
Drug session × group No significant clusters
Main effect of the group Midbrain 13 15,− 7,− 10 19.13 0.003 AD4HC,PD
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effects on MID reward anticipatory BOLD response of
GSK598809 and amphetamine, which releases dopamine.
Amphetamine increases tonic dopamine levels but decreases
reward anticipatory BOLD response (Knutson et al, 2004). In
contrast, by blocking D3 autoreceptors, GSK598809 may
enhance phasic dopamine reward signaling (Sokoloff et al,
2006) and reward anticipatory BOLD response. This reward
enhancing effect of dopamine autoreceptor blockade is
supported by a recent study demonstrating low doses of
the D2/D3 antagonist amisulpride (chosen to result in
preferential autoreceptor blockade) increased MID reward
responsivity in depressed patients (Admon et al, 2016).
Despite these BOLD enhancing effects of GSK598809, no
behavioral effects were found. This may reflect ceiling
effects as the behavioral requirements of the MIDT are very
simple—reaction times were unimpaired in the placebo
condition, suggesting that participants were already perform-
ing at maximum capacity for a speeded motor response.
Furthermore, 60 mg of GSK598809 results in only partial D3
blockade (Erritzoe et al, 2014), therefore behavioral effects
may emerge with increasing dose.
Although no significant drug-by-group interactions were
found, the effects of GSK598809 appeared to be largely
driven by effects within the abstinent drug-dependent groups
rather than controls (especially within the DRD3-rich VP
where a strong trend to an interaction was observed). These
patterns may be due to upregulation of DRD3s in stimulant
and alcohol dependence (Boileau et al, 2012; Erritzoe et al,
2014; Payer et al, 2014; Staley and Mash, 1996) and evidence
of enhanced dopamine autoreceptor actions in response to
chronic exposure to alcohol (Siciliano et al, 2016). While
requiring replication in a larger sample, exploratory
investigations raised the intriguing possibility that
GSK598809 may be relatively ineffective in opiate depen-
dence. At the time of writing, we were unable to find any
published studies on DRD3 density in human opiate addicts.
However, in contrast to the increases in DRD3 expression in
rodents after alcohol and cocaine exposure (Le Foll and Di
Figure 2 ROI response during the MID task: mean reward-neutral anticipation BOLD contrast estimate for both the placebo and the GSK598809 sessions.
White bars represent the placebo session, whereas light gray/blue (when in color) represent the GSK598809 session. Histograms on the top show the main
effect of drug within each ROI (*po0.01, **po0.001), whereas histograms below show the BOLD contrast estimates for the placebo and GSK598809 sessions
for each group separately (†significant effect of group at po0.01 in the placebo condition only). Error bars indicate within-subject SEM (Cousineau and O’Brien,
2014) suitable for assessing drug rather than group effects. A full color version of this figure is available at the Neuropsychopharmacology journal online.
Figure 3 ROI response during the GNG task: mean ‘stops-go’ BOLD contrast estimate within each ROI for the placebo (white bars) and the GSK598809
(gray or blue when in color) sessions. Error bars indicate within-subject SEM (Cousineau and O’Brien, 2014). *Main effect of group, significant at a Bonferroni
corrected value of po0.017. A full color version of this figure is available at the Neuropsychopharmacology journal online.
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Ciano, 2015), a very recent study demonstrated that heroin
exposure decreased DRD3 expression (Zhu et al, 2016),
possibly explaining the apparent reduced efficacy of
GSK598809 in those with a primary opiate dependence.
In addition to effects within DRD3-rich regions, whole-
brain analyses revealed effects within the caudate, cerebel-
lum, and DLPFC. In vivo PET studies do not report high
DRD3 levels within these regions. An enhanced MIDT
reward anticipatory caudate response was also found with
DRD3 receptor blocking doses of amisulpride (Admon et al,
2016). There is evidence supporting the caudate, lateral
prefrontal regions, and cerebellum to be important regions
mediating the integration of motivation with goal-directed
behavior (Harsay et al, 2011; Schutter, 2013; Watanabe and
Sakagami, 2007). Enhanced activation within these regions
may therefore be a downstream consequence of GSK598809’s
effects on the VS and VP, regions critically involved
in incentive motivation (Haber and Knutson, 2010; Smith
et al, 2009).
Together, these findings suggest hypofunctioning of
reward signaling in substance dependence. Evidence sug-
gests, in alcohol and stimulant dependence, that this may be
caused, in part, by excessive D3 autoreceptor inhibition of
dopamine systems. GSK898809 may ameliorate reward
deficits by disinhibiting these systems.
GNG
In contrast to GNG studies demonstrating prefrontal
hypoactivation and impaired response inhibition in current
dependence, we found hyperactivation of lateral prefrontal
regions (PD group) or midbrain (AD group) together with
unimpaired behavioral performance. Our results are con-
sistent with two other studies in cocaine and alcohol
abstinence (Bell et al, 2014; Connolly et al, 2012). They
perhaps reflect recovery of prefrontal structure and function
in successful abstinence owing to cessation of drug use and
cognitive control practices (Garavan et al, 2013). Whether
this hyperactivation, which is also found in relatives of
alcohol patients, is protective for relapse or an addiction
vulnerability marker is unknown. However, fMRI hyper-
activation during cognitive tasks has been reported in
detoxified alcohol-dependent participants who subsequently
abstained but not in those who relapsed (Charlet et al, 2014),
supporting the notion that prefrontal hyperactivation may be
protective.
Despite previous studies suggesting a link between over-
expression of DRD3s and increased impulsivity as measured
by questionnaire (Boileau et al, 2012; Payer et al, 2014), we
found no evidence to suggest GSK598809-modulated per-
formance or neuronal response of the network underlying
response inhibition. This may be due to the multifaceted
nature of impulsivity, with DRD3s affecting some impulsiv-
ity measures but not response inhibition as measured here.
We found no association between a questionnaire measure of
impulsivity and GNG brain response or performance.
Furthermore, while mood-related impulsivity correlates
more strongly with D2/D3 binding in the ventral rather
than dorsal striatum in pathological gamblers (Clark et al,
2012), response inhibition correlates with receptor binding in
the dorsal (where DRD3 density is low) but not the VS
(Ghahremani et al, 2012). These findings suggest that
different impulsivity measures have different underlying
neuro-circuitry. Prefrontal regions are important for re-
sponse inhibition (Aron et al, 2003; Garavan et al, 2013),
again regions where DRD3s are low. Low DRD3 density in
regions implicated in response inhibition may explain the
lack of a modulatory effect of GSK598809 in our study. We
additionally carried out exploratory investigations within the
DRD3-rich regions for the GNGT. However, no effects of
GSK598809 modulations were found. These findings suggest
that D3 agents selectively modulate brain mechanisms of
incentive motivation.
Limitations
The main limitation of the study was the introduction of an
order confound, arising from (ultimately groundless) concerns
over study dropout. However, practice and habituation effects
were minimized by all participants having carried out the
tasks in full within the scanner at screening (placebo session
was either the second or third task scanning session), and the
tasks being practiced outside the scanner before each session.
A post hoc exploratory ROI analysis was carried out within the
anterior insula, a region considered to process salience and
therefore likely to be sensitive to habituation effects. Notably,
the anterior insula is reliably implicated in MID performance
(in a meta-analysis performed by our group) but is devoid of
DRD3s. No effects of GSK598809 or interactions were found
within this region, supporting the suggestion that the effects
seen were indeed drug effects rather than non-specific
habituation effects. Another limitation is the age difference
between the AD and PD groups (consistent with typical
clinical presentation), therefore caution should be used when
interpreting AD vs PD differences.
CONCLUSION
GSK598809 enhances reward anticipatory BOLD response to
non-drug rewards within abstinent substance-dependent
groups, with strongest effects in those with a primary alcohol
dependence. These results have implications for considering
D3 antagonism as a potential treatment for normalizing
reward deficiencies in substance dependence.
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